Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.

Lu XU; Shu Qing YU; Le Gao; Yi Huang; Shan Shan WU; Jun Yang; Yi Xin Sun; Zhi Rong Yang; San Bao Chai; Yuan Zhang; Li Nong JI; Feng Sun; Si Yan Zhan

Return

Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.

Author: Lu XU ¹ ; Shu Qing YU ¹ ; Le GAO ¹ ; Yi HUANG ² ; Shan Shan WU ³ ; Jun YANG ¹ ; Yi Xin SUN ¹ ; Zhi Rong YANG ⁴ ; San Bao CHAI ⁵ ; Yuan ZHANG ⁶ ; Li Nong JI ⁷ ; Feng SUN ¹ ; Si Yan ZHAN ¹
Author Information

1. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
2. Department of Mathematics and Statistics, University of Maryland Baltimore County, Baltimore MD 21250, Maryland, USA.
3. National Clinical Research Center of Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
4. The Primary Care Unit, School of Clinical Medicine, University of Cambridge, Cambridge CB2 1TN, UK.
5. Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing 102206, China.
6. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton L8S 4L8, Ontario, Canada.
7. Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.
Publication Type:Journal Article
Keywords: Body mass index; Body weight; Diabetes mellitus; Dipeptidyl-peptidase IV inhibitors; Glucagon-like peptide-1 receptor agonists; Network meta-analysis; Waist circumference
From: Biomedical and Environmental Sciences 2020;33(1):37-47
CountryChina
Language:English
Abstract: Objective:To evaluate the effects of incretin-based therapies on body weight as the primary outcome, as well as on body mass index (BMI) and waist circumference (WC) as secondary outcomes.
Methods:Databases including Medline, Embase, the Cochrane Library, and clinicaltrials.gov (www.clinicaltrials.gov) were searched for randomized controlled trials (RCTs). Standard pairwise meta-analysis and network meta-analysis (NMA) were both carried out. The risk of bias (ROB) tool recommended by the Cochrane handbook was used to assess the quality of studies. Subgroup analysis, sensitivity analysis, meta-regression, and quality evaluation based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) were also performed.
Results:A total of 292 trials were included in this study. Compared with placebo, dipeptidyl-peptidase IV inhibitors (DPP-4Is) increased weight slightly by 0.31 kg [95% confidence interval ( ): 0.05, 0.58] and had negligible effects on BMI and WC. Compared with placebo, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lowered weight, BMI, and WC by -1.34 kg (95% : -1.60, -1.09), -1.10 kg/m (95% : -1.42, -0.78), and -1.28 cm (95% : -1.69, -0.86), respectively.
Conclusion:GLP-1 RAs were more effective than DPP-4Is in lowering the three indicators. Overall, the effects of GLP-1 RAs on weight, BMI, and WC were favorable.